Mary Vo, MD
Neurology · Houston, TXNPI 1649439266
Payments from drug & device makers
Across 37 payments — averaging $1220.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$28K
- Argenx US, Inc.$9K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- AstraZeneca$76
- UCB, Inc.$43
- Springworks Therapeutics, Inc.$27
- plus $82 from 4 others
Across 10 payments — averaging $197.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Consulting fees$10,12560%
- Travel & lodging$5,71334%
- Food & beverage$9145%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 4 | $28,388 |
| Argenx US, Inc. | 11 | $8,957 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $7,568 |
| AstraZeneca | 2 | $76 |
| UCB, Inc. | 1 | $43 |
| Springworks Therapeutics, Inc. | 1 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,140 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 57 | $423,194 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 35 | $343,673 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 21 | $127,711 |
| Nurtec OdtRimegepant Sulfate | 30 | $47,487 |
| Emgality PenGalcanezumab-Gnlm | 23 | $22,544 |
| Duloxetine Hcl | 81 | $4,304 |
| Gabapentin | 141 | $3,109 |
| Pyridostigmine Bromide | 15 | $1,645 |
| Nortriptyline Hcl | 33 | $1,320 |
| Pregabalin | 56 | $1,201 |
| RizatriptanRizatriptan Benzoate | 30 | $870 |
| Azathioprine | 16 | $665 |
| Propranolol Hcl | 15 | $313 |
| Baclofen | 13 | $292 |
| Amitriptyline Hcl | 11 | $288 |
Paid to pharmacies, not to this prescriber.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.